Mithra Pharmaceuticals Reports 2016 Annual Results
Liège, Belgium, 2 March 2017- Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women's health, today announces its results for the year ended 31 December 2016, prepared in accordance with IFRS.
KEY HIGHLIGHTS
Operational & Corporate Highlights (including post-period end)
Phase III Estelle® oral contraceptive studies, E4Freedom, initiated in EU and US
Partnership agreement signed with Fuji Pharma to commercialize Estelle® in Japan and ASEAN
KEY HIGHLIGHTS
Operational & Corporate Highlights (including post-period end)
Phase III Estelle® oral contraceptive studies, E4Freedom, initiated in EU and US
Partnership agreement signed with Fuji Pharma to commercialize Estelle® in Japan and ASEAN